Cord blood and peripheral blood both yield natural killer cells, and the two are treated as interchangeable far more often than the biology justifies. They differ in maturation state, in receptor repertoire, in how they behave on expansion and in the practical matter of how many cells a single donation yields. For an allogeneic program those differences decide which source fits the process.
A less mature starting population, for better and worse
Cord blood natural killer cells are developmentally younger than their adult peripheral blood counterparts. The population carries a higher proportion of the CD56 bright subset, shows a less differentiated receptor profile, and is generally described as having lower baseline cytotoxicity before activation.
That immaturity is not simply a deficit. A less differentiated population has more proliferative capacity, which matters when a process depends on substantial ex vivo expansion, and it is less likely to carry the exhaustion and terminal differentiation features that accumulate in an adult donor with a lifetime of antigen exposure.
| Attribute | Cord blood derived | Adult peripheral blood derived |
|---|---|---|
| Maturation state | Less differentiated, more CD56 bright | More mature, CD56 dim predominant |
| Baseline cytotoxicity before activation | Generally lower | Generally higher |
| Expansion potential | Typically favorable | Adequate, more donor dependent |
| CMV-driven adaptive NK populations | Absent, the donor has not been exposed | Present in seropositive donors, sometimes substantially |
| Cells per single donation | Limited by collection volume | Large, apheresis-scale |
The cytomegalovirus point is the one most often missed
Cytomegalovirus infection drives expansion of adaptive or memory-like natural killer populations in adults, and in seropositive donors these can make up a considerable share of the compartment. They behave differently from conventional natural killer cells in receptor expression and in response to stimulation.
Cord blood donors have not been exposed, so the population is free of that variable entirely. For a program that wants a uniform starting population, that is a genuine advantage. For a program specifically interested in adaptive natural killer biology, cord blood is the wrong source and an adult donor selected by CMV serostatus is the right one. CMV status is available as a donor selection parameter, subject to availability.
Related product
CD56+ NK cells. Cryopreserved NK cells from single donors, with KIR genotype available on the donor record.
KIR genotype belongs in the selection criteria
Killer immunoglobulin-like receptor genotype varies between individuals and shapes how a natural killer population responds to a given target, particularly in the context of HLA class I on the target cell. For allogeneic work where the relationship between donor receptor repertoire and recipient or target HLA is part of the design, selecting on KIR genotype is more informative than selecting on donor demographics.
KIR genotyping is included in donor characterization rather than ordered separately, and high-resolution NGS HLA typing across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP is performed alongside it. HLA-C is particularly relevant here given its role as a ligand for several inhibitory receptors.
Yield per donation is the practical constraint
A cord blood collection is limited by the volume obtainable at birth, which is modest compared with an adult apheresis collection. A peripheral blood leukopak from a single adult donor provides a minimum of ten billion cells per unit, and adult donors can be scheduled for repeat collection where they are eligible.
The practical consequence is that a process requiring very large numbers of cells from a single donor identity is easier to serve from peripheral blood, while a process built around expansion from a smaller, less differentiated starting population fits cord blood. This is a process design question rather than a quality question, and it is worth answering before the source is fixed.
Published specifications for the isolated products
Cord blood derived CD56 positive natural killer cells are supplied at one million or two and a half million cells per vial, with viability listed at 90 percent or above and CD56 positive purity listed at 90 percent or above, prepared by immunomagnetic selection. Peripheral blood derived natural killer cells are supplied at five million or ten million cells per vial with post-thaw viability listed at 85 percent or above. Both are available in research and cGMP formats.
Note that the specifications differ between the two sources, so a process validated against one set should not assume the other. The difference in vial size in particular affects how many vials a given experiment consumes.
Choosing between research and cGMP format
cGMP format uses GMP-grade input materials, requires a clinical master services agreement, adds testing including sterility, extends documentation and signature requirements, adds Medical Director and Lab Director review, and requires Quality Assurance release rather than technical release. It is manufactured for further manufacturing and is not, by virtue of being cGMP, suitable for direct human administration.
For discovery and process development work, research format is normally the correct choice, with the cGMP question deferred until the process is stable enough that comparability between the two formats can be assessed deliberately.
Related material: cord blood derived NK cells, peripheral blood derived NK cells, and natural killer cell biology.
Frequently asked questions
Are cord blood and peripheral blood NK cells interchangeable?
Not really. They differ in maturation state, receptor repertoire, expansion behavior and yield per donation. Cord blood cells are less differentiated with generally lower baseline cytotoxicity and favorable expansion potential; adult cells are more mature.
Why does cytomegalovirus status matter for NK sourcing?
Cytomegalovirus drives expansion of adaptive, memory-like natural killer populations in adults, which can form a considerable share of the compartment in seropositive donors. Cord blood donors have not been exposed, so that variable is absent.
Should KIR genotype be specified?
For allogeneic work, yes. KIR genotype shapes the response to a given target in the context of target HLA class I. It is included in donor characterization alongside high-resolution HLA typing, so it costs nothing to request and cannot be recovered later.
What are the published specifications?
Cord blood derived CD56 positive NK cells are supplied at one million or two and a half million cells per vial, viability listed at 90 percent or above and CD56 positive purity at 90 percent or above, by immunomagnetic selection. Peripheral blood NK cells are five million or ten million per vial with post-thaw viability listed at 85 percent or above.
Which source suits a process needing very large cell numbers?
Peripheral blood, because a leukopak from a single adult donor provides a minimum of ten billion cells per unit and eligible donors can be scheduled for repeat collection. Cord blood collection volume is limited by what is obtainable at birth.
Does cGMP format mean the cells can be given to a patient?
No. cGMP starting material is manufactured for further manufacturing and is not, by virtue of being cGMP, suitable for direct human administration. It also requires a clinical master services agreement and Quality Assurance release.
What viability specification applies to this material?
Disease-state donor material carries a post-thaw viability specification above 80 percent. That figure applies to the disease-state line specifically and is not carried across from healthy donor products.
Can this material be used for clinical manufacturing?
No. Disease-state donor material is supplied for research use covering discovery, drug screening and biomarker work. Material intended for further manufacturing is a separate cGMP scope with its own agreement and documentation requirements.
Talk to OrganaBio
Need this material for a specific process?
Formats, vial sizes and donor characterization vary by product, and custom formats are documented where a process needs them. Tell us what your process requires and the scientific team will confirm what can be supplied.
